Arcutis Biotherapeutics, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Q2 2026 ZORYVE net product sales reached $129.9M (+59% YoY, +23% sequential), driving upward revision of full-year 2026 net product sales guidance from $480–$495M to $525–$540M. FDA approved pediatric plaque psoriasis expansion for children age 2+, accepted sNDA for infants with atopic dermatitis (PDUFA Feb 23, 2027), and Phase 2 vitiligo enrollment completed. Company swung to Q2 net income of $15.0M ($0.11/share) from Q2 2025 loss of $15.9M, with positive operating cash flow of $12.6M.
Why this rating
Strong commercial momentum (59% growth, $525–540M FY guidance ~35% of $1.5B market cap) and regulatory progress are material. Profitability inflection and sustained cash flow reduce risk, but company remains dependent on single-product franchise.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.